Winston, Alan

Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder:A consensus report of the mind exchange program

The Mind Exchange Working Group, Antinori, A., Arendt, G., Grant, I., Letendre, S., Chair, Munoz-Moreno, J. A., Eggers, C., Brew, B., Brouillette, M.-J., et al. (2013) · Clinical Infectious Diseases

HIV Research and TreatmentInfectious Diseases and Tuberculosis

Cited by 208

Neuroinflammation in treated HIV-positive individuals: A TSPO PET study

Vera, J. H., Guo, Q., Cole, J. H., Boasso, A., Greathead, L., Kelleher, P., Rabiner, E. A., Kalk, N., Bishop, C., Gunn, R. N., et al. (2016) · Neurology

HIV Research and TreatmentNeuroinflammation and Neurodegeneration Mechanisms

Cited by 188

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Pollock, K. M., Cheeseman, H. M., Szubert, A. J., Libri, V., Boffito, M., Owen, D., Bern, H., McFarlane, L. R., O'Hara, J., Lemm, N.-M., et al. (2022) · eClinicalMedicine

SARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene Delivery

Cited by 173

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 6